Timeline

1996

A Company is born, a Purpose is born

With 25 years of history in the health sector, Viveo was found in 1996 by Carlos Mafra, with the constitution of Mafra to operate in the segment of distribution of hospital materials and medicines.

2002

Expansion and Leadership

The Company expanded its operation to the North, Northeast, Central West and other Southeastern states in 2022, through BSB Hospital (incorporated in 2017).

2013

Foundation of Mafra Log

Health Log, as it is known today, has its own fleet and offers a platform of services and solutions that optimize the supply chain for the health market.

2016

Entry of DNA Capital Investment Fund.

2017

Acquisition of Tecnocold Vacinas, a company specialized in vaccine solutions.

2018

Professional management and Cremer Acquisition

The Company accelerated the transition process from management to market executives and promoted the consolidation of acquisitions of assets in the health sector, as well as the integration of cultural and business models of these assets. In April of the same year, it began to verticalize its portfolio and acquired Cremer, a company with more than 85 years of history and with major activities in the manufacture of products for health care in the areas of first aid, surgery, treatment and hygiene.

2019

Ecosystem creation

History of expansion, through companies directly or indirectly linked to the group, has grown through investments made by shareholders with organic growth and M&As.

2019

Team building, long-term strategic plan, fundraising process and continuation of the M&As agenda.

2020

Accelerated growth with acquisitions

Acquisition of Expressa, a company that has been operating in the distribution of hospital medicines for over 30 years.

Acquisition of Flexicotton, Biogenetix, Vitalab and Byogene and participation in the capital of Far.Me, expanding the portfolio of products distributed and sold by the Company.

The Company also invested in the logistics network to increase capillarity and improve the provision of services, which resulted in an increase in the offer of services to customers and suppliers through innovation and the development of new technologies.

2021

In August Viveo held its IPO, moving R$ 1.9 billion in common shares under the ticker VVEO3 initially priced at R$ 19.92.

The opening of capital was a historical milestone for Viveo, which became part of b3’s platform as one of the main players in the health market in Brazil.

2021

Acquisitions of Daviso, FW, Profarma Specialty, Cirúrgica Mafra, Tecno4, Pointmed, Apijã, Laborsys, Macromed, Medcare and BEMK.

Always seeking to capture strategic synergies, expand operations and add value to the ecosystem of products and services, these acquisitions meet Viveo’s mission to simplify the health market through complete, agile, and innovative solutions for the entire chain.

With 25 years of history in the health sector, the Mafra Group (now Viveo) was founded in 1996 by Carlos Mafra, with the establishment of Mafra Cirúrgica to operate in the distribution of hospital materials and medicines. The Company, in turn, was incorporated on August 9, 2010 in the city of Catalão, State of Goiás, becoming an integral part of the Mafra Group.

Primarily, its main activity was the export, import, distribution and representation of medicines, exercising, directly or indirectly, the wholesale trade of drugs, medicines in their original packaging, pharmaceutical supplies and other products related to health.

In January 2013, the Company changed its headquarters to the city of Ribeirão Preto, State of São Paulo, and, in December 2015, it was transformed into a privately-held corporation.

In the course of their operations, the companies directly or indirectly linked to the group, including the Company, grew through investments made by shareholders, the generation of equity capital and through the acquisition of assets. In 2016, the Company and the group reviewed growth strategies and the strengthening of its corporate governance, through planning the gradual implementation of a Code of Conduct and specific policies, such as the Anti-Corruption Policy, new rules for the Audit Committee, Risks, Compliance and Human Resources, and providing compliance training to employees.

In 2017, the Company acquired from Tecnocold –Promoção de Vendas e Participações Ltda. (“Tecnocold Vacinas”), a company specializing in vaccine solutions.

In 2018, the Company accelerated the process of transition from management to market executives and promoted the consolidation of acquisitions of assets in the health sector, as well as the integration of cultural and business models of these assets to the Company and to the group companies. In April of the same year, the Company acquired 91.09% of the capital stock of Cremer SA (“Cremer”), a company with 84 years of history and main activities in the supply of health care products in the areas of first aid, surgery, treatment and hygiene and manufacturing operations in the city of Blumenau, state of Santa Catarina, state of São Paulo and state of Minas Gerais, with 5 distribution centers in different states of Brazil. In October 2018, the Company carried out a public offering for the acquisition of shares that culminated in the acquisition of the residual balance of Cremer’s shares, so that, as of that date, it became the holder of 100.00% of Cremer’s capital stock.

In 2019, the execution of synergies between the companies of the group continued and the search for business strategies focused on simplification, innovation and integration of operations was continued. In December of that same year, the contract for the purchase of 100.00% of the quotas of Expressa Distribuidora de Medicamentos Ltda was signed. (“Expressa”), a company that has been operating for over 30 years in the distribution of hospital medicines.

In 2020, the Company experienced accelerated growth, with the acquisition of the entire share capital of Flexicotton Indústria e Comércio de Produtos de Higiene S.A. (“Flexicotton”), from Biogenetix Importação e Export Ltda. (“Biogenetix”), by Vitalab – Comércio de Produtos para Laboratórios Ltda. (“Vitalab”), by Expressa and Byogene Comércio de Produtos para Laboratório Clínico e Hospitalar Ltda. (“Byogene”) and 35.71% of the share capital of Far.Me Farmacooterapia Otimizada SA (“Far.Me”), through which the portfolio of products distributed and sold by the Company and the companies of the group. The Company also made investments in the logistics network to increase its reach and improve the provision of services, which resulted in an increase in the offer of services to customers and suppliers through innovation and the development of new technologies.

In 2021, the Company continued its growth trajectory, creating a new institutional brand, going public on the Brazilian stock exchange and carrying out several strategic acquisitions. The group reorganized its entire health ecosystem with the mission to simplify this market and with the purpose of taking care of each life. With this structure and present in all links of this chain, Viveo was born, bringing together all companies in an integrated manner, from the production chain, through distribution to the final consumer. The IPO held on August 9 moved R$1.9 billion in ON shares and represented a historic milestone for the Company, which also advanced in the M&As agenda through the acquisitions of Daviso, FW, Profarma Specialty, Cirúrgica Mafra, Tecno4, Pointmed , Apijã, Laborsys, Macromed, Medcare and BEMK. Always seeking to capture strategic synergies, expand operations and add value to the ecosystem of products and services, these acquisitions meet Viveo’s mission of simplifying the healthcare market though complete, agile and innovative solutions for the entire chain.

Site Map